<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00568555</url>
  </required_header>
  <id_info>
    <org_study_id>SU-10232007-756</org_study_id>
    <secondary_id>8948</secondary_id>
    <nct_id>NCT00568555</nct_id>
  </id_info>
  <brief_title>Effects of Low Dose Naltrexone in Fibromyalgia</brief_title>
  <official_title>Effects of Low Dose Naltrexone in Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Fibromyalgia Syndrome Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      Low Dose Naltrexone (LDN) has been reported anecdotally to reduce the symptoms of
      Fibromyalgia, a Chronic Multisystem Illness. The drug may work by regulating natural
      pain-reducing systems. In this study, we will administer both LDN and placebo to a small
      group of individuals with Fibromyalgia and Gulf War Syndrome, both Chronic Multisymptom
      Illnesses, to assess the drug's efficacy in treating the condition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a placebo-controlled, double-blind, cross-over drug tria. Patients with
      Primary Fibromyalgia or Gulf War Syndrome will be recruited from the Stanford University Pain
      Management Center and the surrounding community. Participation in the study will cover 22
      weeks. Participants will attend a laboratory session 12 times for progress checkups, and will
      complete daily measures of symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Pain Scores Between Baseline to End of Placebo Treatment and Between Baseline to End of LDN Treatment.</measure>
    <time_frame>Baseline to end of placebo (2 weeks + 4 weeks) and baseline to end of LDN (2 weeks + 12 weeks)</time_frame>
    <description>Visual Analogue Scale for pain, 0 to 100, where 0=no pain and 100=worst pain imaginable.
Baseline pain calculated averaging daily pain scores over the 2 week baseline period.
Placebo and LDN pain scores calculated by averaging daily pain scores during the final 3 days of each condition.
Values were converted to percent change in pain: [(baseline pain - end point pain)/baseline pain] x 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Sleep Quality Scores Between Baseline to End of Placebo Treatment and Between Baseline to End of LDN Treatment.</measure>
    <time_frame>Baseline to end of placebo (2 weeks + 4 weeks) and baseline to end of LDN (2 weeks + 12 weeks)</time_frame>
    <description>Visual Analogue Scale for sleep quality, 0 to 100, where 0 = &quot;did not sleep well at all&quot; and 100 = &quot;slept extremely well&quot;.
Baseline sleep quality calculated by averaging daily scores over the 2 week baseline period.
Placebo and LDN sleep quality scores calculated by averaging daily scores during the final 3 days of each condition.
Values were converted to percent change in sleep quality: [(baseline sleep - end point sleep)/baseline sleep] x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Fatigue Scores Between Baseline to End of Placebo Treatment and Between Baseline to End of LDN Treatment.</measure>
    <time_frame>Baseline to end of placebo (2 weeks + 4 weeks) and baseline to end of LDN (2 weeks + 12 weeks)</time_frame>
    <description>Visual Analogue Scale for fatigue, 0 to 100, where 0 = &quot;no fatigue at all&quot; and 100 = &quot;severe fatigue&quot;.
Baseline fatigue calculated averaging daily scores over the 2 week baseline period.
Placebo and LDN fatigue scores calculated by averaging daily scores during the final 3 days of each condition.
Values were converted to percent change in fatigue: [(baseline fatigue - end point fatigue)/baseline fatigue] x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Pressure Pain Threshold Between Baseline and End of Placebo Treatment and Between Baseline to End of LDN Treatment.</measure>
    <time_frame>Baseline to end of placebo (2 weeks + 4 weeks) and baseline to end of LDN (2 weeks + 12 weeks)</time_frame>
    <description>An algometer is used to apply pressure to 18 points across the body. Pressure is applied until the first sensation of pain in indicated. This pressure is recorded (as kg/cm2) and averaged for all 18 points to provide an overall score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Heat Pain Sensitivity Between Baseline and End of Placebo Treatment and Between Baseline to End of LDN Treatment.</measure>
    <time_frame>Baseline to end of placebo (2 weeks + 4 weeks) and baseline to end of LDN (2 weeks + 12 weeks)</time_frame>
    <description>A thermode is placed on the palm, and temperature is increased until the first sensation of pain. That temperature is recorded in Degrees Celsius . The procedure is repeated 3 times and results are averaged into a single temperature recording.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Fibromyalgia</condition>
  <condition>Persian Gulf Syndrome</condition>
  <arm_group>
    <arm_group_label>Low Dose Naltrexone first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDN first, then placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - sugar pill first</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo first, then LDN.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose Naltrexone</intervention_name>
    <description>3-4.5mg Naltrexone once daily</description>
    <arm_group_label>Low Dose Naltrexone first</arm_group_label>
    <arm_group_label>Placebo - sugar pill first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - sugar pill</intervention_name>
    <description>Placebo pill once daily</description>
    <arm_group_label>Low Dose Naltrexone first</arm_group_label>
    <arm_group_label>Placebo - sugar pill first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Currently suffering from moderate to severe Fibromyalgia or symptoms of Gulf War Syndrome
        Age 18-65. Not taking any opioid analgesic Not pregnant or planning to become pregnant.

        Exclusion Criteria:

        Any known allergy to naltrexone or naloxone. Actual or planned pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jarred Younger</last_name>
    <role>Sub-Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2007</study_first_submitted>
  <study_first_submitted_qc>December 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2007</study_first_posted>
  <results_first_submitted>April 10, 2013</results_first_submitted>
  <results_first_submitted_qc>September 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 21, 2015</results_first_posted>
  <last_update_submitted>September 21, 2015</last_update_submitted>
  <last_update_submitted_qc>September 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Sean Mackey</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Persian Gulf Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>325 women completed an online web survey</recruitment_details>
      <pre_assignment_details>Individuals were assessed for eligibility via web screening and phone screening prior to enrollment.
Further eligibility (blood tests, questionnaires) assessed after enrollment; ineligible consented participants were withdrawn prior to assignment to groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Dose Naltrexone First</title>
          <description>Low Dose Naltrexone (LDN) followed by placebo. LDN at 3-4.5mg, once a day. Placebo (sugar pill) once a day.</description>
        </group>
        <group group_id="P2">
          <title>Placebo - Sugar Pill First</title>
          <description>Placebo first, followed by LDN. Placebo (sugar pill) once a day. LDN at 3-4.5mg, once a day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>2 participants in the low dose naltrexone group did not have data to analyze (1 withdrew by patient choice, 1 had a malfunction with the data collection device)
1 participant in the placebo condition did not have data to analyze (withdrew by patient choice)</population>
      <group_list>
        <group group_id="B1">
          <title>Low Dose Naltrexone</title>
        </group>
        <group group_id="B2">
          <title>Placebo - Sugar Pill</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.8" spread="13.4"/>
                    <measurement group_id="B2" value="42.3" spread="13.0"/>
                    <measurement group_id="B3" value="42.7" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Pain Scores Between Baseline to End of Placebo Treatment and Between Baseline to End of LDN Treatment.</title>
        <description>Visual Analogue Scale for pain, 0 to 100, where 0=no pain and 100=worst pain imaginable.
Baseline pain calculated averaging daily pain scores over the 2 week baseline period.
Placebo and LDN pain scores calculated by averaging daily pain scores during the final 3 days of each condition.
Values were converted to percent change in pain: [(baseline pain - end point pain)/baseline pain] x 100.</description>
        <time_frame>Baseline to end of placebo (2 weeks + 4 weeks) and baseline to end of LDN (2 weeks + 12 weeks)</time_frame>
        <population>All completers</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone</title>
            <description>All participants during the Low Dose Naltrexone condition</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Sugar Pill</title>
            <description>All participants during the placebo condition</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Pain Scores Between Baseline to End of Placebo Treatment and Between Baseline to End of LDN Treatment.</title>
          <description>Visual Analogue Scale for pain, 0 to 100, where 0=no pain and 100=worst pain imaginable.
Baseline pain calculated averaging daily pain scores over the 2 week baseline period.
Placebo and LDN pain scores calculated by averaging daily pain scores during the final 3 days of each condition.
Values were converted to percent change in pain: [(baseline pain - end point pain)/baseline pain] x 100.</description>
          <population>All completers</population>
          <units>percentage change from baseline to final</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" lower_limit="19.5" upper_limit="38.1"/>
                    <measurement group_id="O2" value="18.0" lower_limit="7.2" upper_limit="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Sleep Quality Scores Between Baseline to End of Placebo Treatment and Between Baseline to End of LDN Treatment.</title>
        <description>Visual Analogue Scale for sleep quality, 0 to 100, where 0 = &quot;did not sleep well at all&quot; and 100 = &quot;slept extremely well&quot;.
Baseline sleep quality calculated by averaging daily scores over the 2 week baseline period.
Placebo and LDN sleep quality scores calculated by averaging daily scores during the final 3 days of each condition.
Values were converted to percent change in sleep quality: [(baseline sleep - end point sleep)/baseline sleep] x 100.</description>
        <time_frame>Baseline to end of placebo (2 weeks + 4 weeks) and baseline to end of LDN (2 weeks + 12 weeks)</time_frame>
        <population>All completers</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone</title>
            <description>All participants during the low dose naltrexone condition</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Sugar Pill</title>
            <description>All participant during the placebo condition</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Sleep Quality Scores Between Baseline to End of Placebo Treatment and Between Baseline to End of LDN Treatment.</title>
          <description>Visual Analogue Scale for sleep quality, 0 to 100, where 0 = &quot;did not sleep well at all&quot; and 100 = &quot;slept extremely well&quot;.
Baseline sleep quality calculated by averaging daily scores over the 2 week baseline period.
Placebo and LDN sleep quality scores calculated by averaging daily scores during the final 3 days of each condition.
Values were converted to percent change in sleep quality: [(baseline sleep - end point sleep)/baseline sleep] x 100.</description>
          <population>All completers</population>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="-35.8" upper_limit="56.6"/>
                    <measurement group_id="O2" value="9.2" lower_limit="-40.6" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Fatigue Scores Between Baseline to End of Placebo Treatment and Between Baseline to End of LDN Treatment.</title>
        <description>Visual Analogue Scale for fatigue, 0 to 100, where 0 = &quot;no fatigue at all&quot; and 100 = &quot;severe fatigue&quot;.
Baseline fatigue calculated averaging daily scores over the 2 week baseline period.
Placebo and LDN fatigue scores calculated by averaging daily scores during the final 3 days of each condition.
Values were converted to percent change in fatigue: [(baseline fatigue - end point fatigue)/baseline fatigue] x 100.</description>
        <time_frame>Baseline to end of placebo (2 weeks + 4 weeks) and baseline to end of LDN (2 weeks + 12 weeks)</time_frame>
        <population>All completers</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone</title>
            <description>All participants during the Low Dose Naltrexone condition</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Sugar Pill</title>
            <description>All participants during the placebo condition</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Fatigue Scores Between Baseline to End of Placebo Treatment and Between Baseline to End of LDN Treatment.</title>
          <description>Visual Analogue Scale for fatigue, 0 to 100, where 0 = &quot;no fatigue at all&quot; and 100 = &quot;severe fatigue&quot;.
Baseline fatigue calculated averaging daily scores over the 2 week baseline period.
Placebo and LDN fatigue scores calculated by averaging daily scores during the final 3 days of each condition.
Values were converted to percent change in fatigue: [(baseline fatigue - end point fatigue)/baseline fatigue] x 100.</description>
          <population>All completers</population>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" lower_limit="-33.2" upper_limit="58.4"/>
                    <measurement group_id="O2" value="7.8" lower_limit="-26.6" upper_limit="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Pressure Pain Threshold Between Baseline and End of Placebo Treatment and Between Baseline to End of LDN Treatment.</title>
        <description>An algometer is used to apply pressure to 18 points across the body. Pressure is applied until the first sensation of pain in indicated. This pressure is recorded (as kg/cm2) and averaged for all 18 points to provide an overall score.</description>
        <time_frame>Baseline to end of placebo (2 weeks + 4 weeks) and baseline to end of LDN (2 weeks + 12 weeks)</time_frame>
        <population>All completers</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone</title>
            <description>All participants during the low dose naltrexone condition</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Sugar Pill</title>
            <description>All participant during the placebo condition</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Pressure Pain Threshold Between Baseline and End of Placebo Treatment and Between Baseline to End of LDN Treatment.</title>
          <description>An algometer is used to apply pressure to 18 points across the body. Pressure is applied until the first sensation of pain in indicated. This pressure is recorded (as kg/cm2) and averaged for all 18 points to provide an overall score.</description>
          <population>All completers</population>
          <units>percentage change from baseline to final</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.70" lower_limit="17.41" upper_limit="56.00"/>
                    <measurement group_id="O2" value="28.26" lower_limit="11.27" upper_limit="45.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Heat Pain Sensitivity Between Baseline and End of Placebo Treatment and Between Baseline to End of LDN Treatment.</title>
        <description>A thermode is placed on the palm, and temperature is increased until the first sensation of pain. That temperature is recorded in Degrees Celsius . The procedure is repeated 3 times and results are averaged into a single temperature recording.</description>
        <time_frame>Baseline to end of placebo (2 weeks + 4 weeks) and baseline to end of LDN (2 weeks + 12 weeks)</time_frame>
        <population>All completers</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone</title>
            <description>All participants during the low dose naltrexone condition</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Sugar Pill</title>
            <description>All participant during the placebo condition</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Heat Pain Sensitivity Between Baseline and End of Placebo Treatment and Between Baseline to End of LDN Treatment.</title>
          <description>A thermode is placed on the palm, and temperature is increased until the first sensation of pain. That temperature is recorded in Degrees Celsius . The procedure is repeated 3 times and results are averaged into a single temperature recording.</description>
          <population>All completers</population>
          <units>percentage change from baseline to final</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" lower_limit="0.40" upper_limit="5.83"/>
                    <measurement group_id="O2" value="3.45" lower_limit="0.93" upper_limit="5.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Low Dose Naltrexone</title>
          <description>All participants during the Low Dose Naltrexone condition</description>
        </group>
        <group group_id="E2">
          <title>Placebo - Sugar Pill</title>
          <description>All participants during the placebo condition</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vivid Dreams</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nausea/Upset Stomach</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nightmares</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dry mouth or throat</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jarred Younger, PhD</name_or_title>
      <organization>Stanford University School of Medicine</organization>
      <phone>650-724-2795</phone>
      <email>jyounger@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

